Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

A double-institution phase II study was performed in patients with metastatic renal cell carcinoma treated subcutaneously (s.c.) with interleukin 2 (IL-2) and alpha-interferon (INF-alpha). Thirty-eight patients were treated over a course of 7 weeks. Initially (day 1 + 2) patients received s.c. IL-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravaud, A., Négrier, S., Cany, L., Merrouche, Y., Le Guillou, M., Blay, J. Y., Clavel, M., Gaston, R., Oskam, R., Philip, T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969444/
https://www.ncbi.nlm.nih.gov/pubmed/8198979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969444/
https://www.ncbi.nlm.nih.gov/pubmed/8198979

Ejemplares similares